Novel strategies in the oral delivery of antidiabetic peptide drugs – Insulin, GLP 1 and its analogs

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 115, Issue , 2017, Pages 257-267

  Ismail, Ruba ^a   Csóka, Ildikó ^a  

^a UNIVERSITY OF SZEGED   (Hungary)

Author keywords

Antidiabetic peptides; Diabetes; GLP 1; Insulin; Liposomes; Micelles; Nano carriers; Polymeric nanoparticles; Quality by design; Solid lipid nanoparticles

Indexed keywords

CELL PENETRATING PEPTIDE; GLUCAGON LIKE PEPTIDE 1; INSULIN; LIPOSOME; NANOPARTICLE; ORAL ANTIDIABETIC AGENT; SOLID LIPID NANOPARTICLE; ANTIDIABETIC AGENT; PEPTIDE;

ACYLATION; BIOTINYLATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; ENHANCER REGION; HUMAN; MICELLE; PEGYLATION; REVIEW; ORAL DRUG ADMINISTRATION; PROCEDURES;

ADMINISTRATION, ORAL; DRUG DELIVERY SYSTEMS; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; PEPTIDES;

EID: 85016085382     PISSN: 09396411     EISSN: 18733441     Source Type: Journal    
DOI: 10.1016/j.ejpb.2017.03.015     Document Type: Review

References (212)

1. [1] Muheem, A., Shakeel, F., Jahangir, M.A., et al. A review on the strategies for oral delivery of proteins and peptides and their clinical perspectives. Saudi Pharm. J. 24:4 (2016), 413–428.
2. [2] Frokjaer, S., Otzen, D.D., Protein drug stability: a formulation challenge. Nat. Rev. Drug Discov. 4:4 (2005), 298–306.
3. [3] Vlieghe, P., Lisowski, V., Martinez, J., et al. Synthetic therapeutic peptides: science and market. Drug Discov. Today 15:1–2 (2010), 40–56.
4. [4] Pawar, V.K., Meher, J.G., Singh, Y., et al. Targeting of gastrointestinal tract for amended delivery of protein/peptide therapeutics: strategies and industrial perspectives. J. Control. Release 196 (2014), 168–183.
5. [5] Craik, D.J., Fairlie, D.P., Liras, S., et al. The future of peptide-based drugs. Chem. Biol. Drug Des. 81:1 (2013), 136–147.
6. [6] Banga, A.K., Therapeutic Peptides and Proteins. Formulation, Processing, and Delivery Systems. 2nd ed., 2006, Taylor & Francis Group: LLC.
7. [7] Torchilin, V.P., Lukyanov, A.N., Peptide and protein drug delivery to and into tumors: challenges and solutions. Drug Discov. Today 8:6 (2003), 259–266.
8. [8] Piero, M.N., Nzaro, G.M., Njagi, J.M., Diabetes mellitus – a devastating metabolic disorder. Asian J. Biomed. Pharm. Sci. 40:4 (2014), 1–7.
9. [9] Stefánsson, E., Einarsdóttir, A.B., Public health and prevention of blindness in diabetes. Int. J. Diabetes Mellitus 3:1 (2015), 1–3.
10. [10] Bangalore, S., Fakheri, R., Tuklo, B., et al. Diabetes mellitus as a compelling indication for use of renin angiotensin system blockers: systematic review and meta-analysis of randomized trials. BMJ, 352, 2016, i438, 10.1136/bmj.i438.
11. [11] Heydari, I., Radi, V., Razmjou, S., et al. Chronic complications of diabetes mellitus in newly diagnosed patients. Int. J. Diabetes Mellitus 2:1 (2010), 61–63.
12. [12] Card, J.W., Magnuson, B.A., A review of the efficacy and safety of nanoparticle-based oral insulin delivery systems. Am. J. Physiol. Gastrointest. Liver Physiol. 301:6 (2011), G956–67.
13. [13] Amsden, B.G., Goosen, M.F.A., Transdermal delivery of peptide and protein drugs: an overview. AIChE J. 41:8 (1995), 1972–1997.
14. [14] Aungst, B., Saitoh, H., Burcham, D., et al. Enhancement of the intestinal absorption of peptides and nanopeptides. J. Control. Release 41:8 (1996), 19–31.
15. [15] Bruno, B.B., Miller, G.D., Lim, C.S., Basics and recent advances in peptide and protein drug delivery. Therap. Drug Del. 4:11 (2014), 1443–1467.
16. [16] Wearly, L.L., Recent progress in peptides and proteins delivery by noninvasive routes. Cri. Rev. Ther. Drug Car. Syst. 8:4 (1991), 331–394.
17. [17] Gibson, M., Pharmaceutical Preformulation and Formulation: A Practical Guide From Candidate Drug Selection to Commercial Dossage Form. 2nd Ed., 2009, Informa Healthcare USA, New York.
18. [18] Kumar, T.R., Soppimath, K., Nachaegari, S.K., Novel delivery technologies for protein and peptide therapeutics. Curr. Pharm. Biotechnol. 7:4 (2006), 261–276.
19. [19] Jitendra, Sharma, P.K., Bansal, S., et al. Noninvasive routes of proteins and peptides drug delivery. Indian J. Pharm. Sci. 73:4 (2011), 367–375.
20. [20] Antosova, Z., Mackova, M., Kral, V., et al. Therapeutic application of peptides and proteins: parenteral forever?. Trends Biotechnol. 27:11 (2009), 628–635.
21. [21] Andrade, F., Videira, M., Ferreira, D., et al. Nanocarriers for pulmonary administration of peptides and therapeutic proteins. Nanomedicine 6:1 (2011), 123–141.
22. [22] Wallis, L., Kleynhans, E., Toit, T.D., et al. Novel non-invasive protein and peptide drug delivery approaches. Protein Pept. Lett. 21:11 (2014), 1087–1101.
23. [23] Sun, S., Liang, N., Yamamoto, H., et al. PH-sensitive poly(lactide-co-glycolide) nanoparticle composite microcapsules for oral delivery of insulin. J. Nanomedicine 10 (2015), 3489–3498.
24. [24] Ahmad, A., Othman, I., Zain, A.Z.M., et al. Recent advances in insulin therapy for diabetes. Int. J. Diabetes Clin. Res., 1(1), 2014, 13.
25. [25] Alai, M.S., Lin, W.J., Pingale, S.S., Application of polymeric nanoparticles and micelles in insulin oral delivery. J. Food Drug Anal. 23:3 (2015), 251–358.
26. [26] Fonte, P., Araújo, F., Silva, C., et al. Polymer-based nanoparticles for oral insulin delivery: revisited approaches. Biotechnol. Adv. 33:6 (2015), 1342–1354.
27. [27] Alibolandi, M., Alabdollah, F., Sadeghi, F., et al. Dextran-b-poly(lactide-co-glycolide) polymersome for oral delivery of insulin: In vitro and in vivo evaluation. J. Control. Release 227 (2016), 58–70.
28. [28] Sharma, G., Sharma, A.R., Nam, J.S., et al. Nanoparticle based insulin delivery system: the next generation efficient therapy for Type 1 diabetes. J. Nanobiotechnol., 74, 2015, 13 .
29. [29] Specian, R.D., Oliver, M.G., Functional biology of intestinal goblet cells. Am. J. Phys. 260:2 (1991), C183–C193.
30. [30] Chen, M.C., Sonaje, K., Chen, K.J., et al. A review of the prospects for polymeric nanoparticle platforms in oral insulin delivery. Biomaterials 32:36 (2011), 9826–9838.
31. [31] Baggio, L.L., Drucker, D.J., Biology of Incretins: GLP-1 and GIP. Gastroenterology 132:6 (2007), 2131–2157.
32. [32] Sandoval, D.A., D'Alessio, D.A., Physiology of proglucagon peptides: role of glucagon and GLP-1 in health and disease. Physiol. Rev. 295:2 (2015), 513–548.
33. [33] Kazakos, K., Incretin effect: GLP-1, GIP, DPP4. Diabetes Res. Clin. Pract. 93:1 (2011), S32–S36.
34. [34] Madsbad, S., Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists. Diabetes Obes. Metab. 18:4 (2016), 317–332.
35. [35] Steinert, R.E., Poller, B., Castelli, M.C., et al. Orally administered glucagon-like peptide-1 affects glucose homeostasis following an oral glucose tolerance test in healthy male subjects. Clin. Pharmacol. Ther. 86:6 (2009), 644–650.
36. [36] Jun, H.S., Bae, G., Ko, Y.T., et al. Cytotoxicity and biological efficacy of exendin-4-encapsulated solid lipid nanoparticles in INS-1 cells. J. Nanomater., 2015, 753569, 10.1155/2015/753569 6p.
37. [37] Kochavi, L.S., Naraykin, N., Nassar, T., et al. Improved oral absorption of exenatide using an original Nanoencapsulation and microencapsulation approach. J. Control. Release 217 (2015), 202–210.
38. [38] Morishita, M., Peppas, A.N., Is the oral route possible for peptide and protein drug delivery?. Drug Discov. Today 11:19-20 (2006), 905–910.
39. [39] Jorgensen, L., Nielson, H.M., Delivery Technologies for Biopharmaceuticals Peptides, Proteins, Nucleic Acid and Vaccines. 2009, John Wiley & Sons, West Sussex.
40. [40] Sharma, A., Arora, S., Commercial challenges and emerging trends in oral delivery of peptide and protein drugs: a review. Res. J. Pharm. Biol. Chem. Sci. 2:3 (2011), 778–790.
41. [41] Yamanaka, Y.J., Leong, K.W., Engineering strategies to enhance nanoparticle-mediated oral delivery. J. Biomater. Sci. Polym. Ed. 19:12 (2008), 1549–1570.
42. [42] Park, K., Kwon, I.C., Park, K., Oral protein delivery: current status and future prospect. React. Funct. Polym. 71:3 (2011), 280–287.
43. [43] Eckford, P.D., Sharom, F.J., ABC efflux pump-based resistance to chemotherapy drugs. Chem. Rev. 109:7 (2009), 2989–3011.
44. [44] Zhou, S.F., Structure, function and regulation of p-glycoprotein and its clinical relevance in drug disposition. Xenobiotica 38:7–8 (2008), 802–832.
45. [45] Varma, M.V., Ashokraj, Y., Dey, C.S., et al. P-glycoprotein inhibitors and their screening: a perspective from bioavailability enhancement. Pharmacol. Res. 48:4 (2013), 347–359.
46. [46] Misra, A., Challenges in Delivery of Therapeutic Genomics and Proteomics. 1st ed., 2011, Elsevier Inc.
47. [47] Jain, D., Panda, A.K., Majumdar, D.K., Eudragit S100 entrapped insulin microspheres for oral delivery. AAPS Pharm. Sci. Tech. 6:1 (2005), E100–E107.
48. [48] Zhang, G.H., Han, B.Z., Lin, X.Y., et al. Modification of antimicrobial peptide with low molar mass poly(ethylene glycol). J. Biochem. 144:6 (2008), 781–788.
49. [49] Abuchowski, A., McCoy, J.R., Palczuk, N.C., et al. Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase. J. Biol. Chem. 252:11 (1977), 3582–3586.
50. [50] Gupta, H., Sharma, A., Recent trends in protein and peptide drug delivery systems. Asian J. Pharm. 3 (2009), 69–75.
51. [51] Pisal, D.S., Kosloski, M.P., Balu-Iyer, S.V., Delivery of therapeutic proteins. J. Pharm. Sci. 99:6 (2010), 2557–2575.
52. [52] Yang, C., Lu, D., Liu, Z., How PEGylation enhances the stability and potency of insulin: a molecular dynamics simulation. Biochemistry 50:13 (2011), 2585–2593.
53. [53] Yin, N., Brimble, M.A., Harris, P.W.R., et al. Enhancing the oral bioavailability of peptide drugs by using chemical modification and other approaches. Med. Chem. 4:12 (2014), 763–769.
54. [54] Ambrosio, E., Barattin, M., Bersani, S., et al. A novel combined strategy for the physical PEGylation of polypeptides. J. Control. Release 226 (2016), 35–46.
55. [55] Nojima, Y., Suzuki, Y., Iguchi, K., et al. Development of poly(ethylene glycol) conjugated lactoferrin for oral administration. Bioconjug. Chem. 19:11 (2008), 2253–2259.
56. [56] Chae, S.Y., Lee, S., Kwon, M.J., et al. Improved peroral delivery of glucagon-like peptide-1 by site-specific biotin modification: design, preparation, and biological evaluation. Eur. J. Pharm. Biopharm. 68:3 (2008), 667–675.
57. [57] Tuesca, A.D., Reiff, C., Joseph, J.I., Lowman, A.M., Synthesis, characterization and in vivo efficacy of PEGylated insulin for oral delivery with complexation hydrogels. Pharm. Res. 26:3 (2009), 727–739.
58. [58] Chaturvedi, K., Ganguly, K., Kulkarni, A.R., et al. Oral insulin delivery using deoxycholic acid conjugated PEGylated polyhydroxybutyrate co-polymeric nanoparticles. Nanomedicine 10:10 (2015), 1569–1583.
59. [59] Goodwin, D., Simerska, P., Toth, I., Peptides as therapeutics with enhanced bioactivity. Curr. Med. Chem. 19 (2012), 4451–4461.
60. [60] Zhang, L., Bulaj, G., Converting peptides into drug leads by lipidation. Curr. Med. Chem. 19:26 (2012), 1602–1618.
61. [61] Li, D., Strategic approaches to optimizing peptide ADME properties. AAPS J. 17:1 (2015), 134–143.
62. [62] Buckley, S.T., Hubálek, F., Rahbek, U.L., Chemically modified peptides and proteins - critical considerations for oral delivery. Tissue Barriers, 4, 2016, e1156805.
63. [63] Zaro, J.L., Lipid-based drug carriers for prodrugs to enhance drug delivery. AAPS J. 17:1 (2015), 83–92.
64. [64] Hackett, M.J., Zaro, J.L., Shen, W.C., et al. Fatty acids as therapeutic auxiliaries for oral and parenteral formulations. Adv. Drug Deliv. Rev. 65:10 (2013), 1331–1339.
65. [65] Hashimoto, M., Takada, K., Kiso, Y., et al. Synthesis of palmitoyl derivatives of insulin and their biological activities. Pharm. Res. 6:2 (1989), 171–176.
66. [66] Jain, R., Chawrai, S., Advancements in the anti-diabetes chemotherapeutics based on amino acids, peptides, and peptidomimetics. Mini. Rev. Med. Chem. 5:5 (2005), 469–477.
67. [67] Varamini, P., Toth, I., Recent advances in oral delivery of peptide hormones. Expert Opin. Drug Deliv. 13:4 (2016), 507–522.
68. [68] Joseph, J.W., Kalitsky, J., St-Pierre, S., et al. Oral delivery of glucagon-like peptide-1 in a modified polymer preparation normalizes basal glycaemia in diabetic db/db mice. Diabetologia 43:10 (2000), 1319–1328.
69. [69] Youn, Y.S., Chae, S.Y., Lee, S., et al. Improved peroral delivery of glucagon-like peptide-1 by site-specific biotin modification: design, preparation, and biological evaluation. Eur. J. Pharm. Biopharm. 68:3 (2008), 667–675.
70. [70] Jin, C.H., Chae, S.U., Son, S., et al. A new orally available glucagon-like peptide-1 receptor agonist, biotinylated exendin-4, displays improved hypoglycemic effects in db/db mice. J. Control. Release 133:3 (2009), 172–177.
71. [71] Maher, S., Ryan, B., Duffy, A., et al. Formulation strategies to improve oral peptide delivery. Pharm. Pat. Anal. 3:3 (2014), 313–336.
72. [72] Renukuntla, J., Vadlapudi, A.D., Patel, A., et al. Approaches for enhancing oral bioavailability of peptides and proteins. Int. J. Pharm. 447:1–2 (2013), 75–93.
73. [73] Tuvia, S., Pelled, D., Marom, K., et al. A novel suspension formulation enhances intestinal absorption of macromolecules via transient and reversible transport mechanisms. Pharm. Res. 31:8 (2014), 2010–2021.
74. [74] Schipper, N.G., Varum, K.M., Artursson, P., Chitosans as absorption enhancers for poorly absorbable drugs. 1: influence of molecular weight and degree of acetylation on drug transport across human intestinal epithelial (Caco-2) cells. Pharm. Res. 13:11 (1996), 1686–1692.
75. [75] Iyer, H., Anand, K., Verma, M., Oral insulin – a review of current status, diabetes. Obes. Met. 12:3 (2010), 179–185.
76. [76] Maher, S., Mrsny, R.J., Brayden, D.J., Intestinal permeation enhancers for oral peptide delivery. Adv. Drug Del. Rev., 2016, 43, 10.1016/j.addr.2016.06.00.
77. [77] Ratnaparkh, M.P., Chaudhari, S.P., Pandya, V.A., Peptides and proteins in pharmaceuticals. Int. J. Curr. Pharm. Res. 3:2 (2011), 1–9.
78. [78] Weinheimer, M., Fricker, G., Burhenne, J., et al. The application of P-gp inhibiting phospholipids as novel oral bioavailability enhancers – an in vitro and in vivo comparison. Eur. J. Pharm. Sci., 2016, 10.1016/j.ejps.2016.08.055.
79. [79] Choonara, B.F., Choonara, Y.E., Kumar, P., et al. A review of advanced oral drug delivery technologies facilitating the protection and absorption of protein and peptide molecules. Biotechnol. Adv. 32:7 (2014), 1269–1282.
80. [80] Moroz, E., Matoori, S., Leroux, J.C., Oral delivery of macromolecular drugs: where we are after almost 100 years of attempts. Adv. Drug Del. Rev. 101 (2016), 108–121.
81. [81] Sonaje, K., Lin, K.J., Tseng, M.T., et al. Effects of chitosan-nanoparticle-mediated tight junction opening on the oral absorption of endotoxins. Biomaterials 32:33 (2011), 8712–8721.
82. [82] Shrestha, N., Shahbazi, M.A., Araújo, F., et al. Multistage pH-responsive mucoadhesive nanocarriers prepared by aerosol flow reactor technology: a controlled dual protein-drug delivery system. Biomaterials 68 (2015), 9–20.
83. [83] Li, L., Jiang, G., Yu, W., et al. Preparation of chitosan-based multifunctional nanocarriers overcoming multiple barriers for oral delivery of insulin. Mater. Sci. Eng., C 70 (2017), 278–286.
84. [84] Lopes, M., Shrestha, N., Correia, A., et al. Dual chitosan/albumin-coated alginate/dextran sulfate nanoparticles for enhanced oral delivery of insulin. J. Control. Release 232 (2016), 29–41.
85. [85] Eldin, M.S.M., Omer, A.M., Wassel, M.A., et al. Novel smart pH sensitive chitosan grafted alginate hydrogel microcapsules for oral protein delivery: II. Evaluation of the swelling behavior. Int. J. Pharm. Pharm. Sci. 7:10 (2015), 331–337.
86. [86] Vllasaliu, D., Exposito-Harris, R., Heras, A., et al. Tight junction modulation by chitosan nanoparticles: comparison with chitosan solution. Int. J. Pharm. 400:1–2 (2010), 183–193.
87. [87] Mukhopadhyay, P., Sarkar, K., Bhattacharya, S., et al. pH sensitive N-succinyl chitosan grafted polyacrylamide hydrogel for oral insulin delivery. Carbohyd. Polym., 112, 2014, 627.
88. [88] Mukhopadhyay, P., Chakraborty, S., Bhattacharya, S., et al. PH-sensitive chitosan/alginate core–shell nanoparticles for efficient and safe oral insulin delivery. Int. J. Biol. Macromol. 72 (2015), 640–648.
89. [89] Liu, M., Zhang, J., Zhu, X., et al. Efficient mucus permeation and tight junction opening by dissociable “mucus-inert” agent coated trimethyl chitosan nanoparticles for oral insulin delivery. J. Control. Release 222 (2015), 67–77.
90. [90] Millotti, G., Laffleur, F., Perera, G., et al. In vivo evaluation of thiolated chitosan tablets for oral insulin delivery. Pharm., Drug Del. Pharm. Technol. 103:10 (2014), 3165–3170.
91. [91] Bernkop-Schnurch, A., Thiomers: a new generation of mucoadhesive polymers. Adv. Drug Del. Rev. 57:11 (2005), 1569–1582.
92. [92] Abbad, S., Zhang, Z., Waddad, A.Y., et al. Chitosan-modified cationic amino acid nanoparticles as a novel oral delivery system for insulin. J. Biomed. Nanotechnol. 11:3 (2015), 486–499.
93. [93] Aungst, B.J., Intestinal permeation enhancers. J. Pharmaceut. Sci. 89:4 (2000), 429–442.
94. [94] Aungst, B.J., Absorption enhancers: applications and advances. AAPS J. 14:1 (2012), 10–18.
95. [95] Li, P., Nielsen, H.m., Fano, M., et al. Preparation and characterization of insulin–surfactant complexes for loading into lipid-based drug delivery systems. J. Pharm. Sci. 102:8 (2013), 2689–2698.
96. [96] Schnürc, A.B., Oral Delivery of Macromolecular Drugs: Barriers, Strategies and Future Trends- Low Molecular Mass Permeation Enhancers In Oral Delivery Of Macromolecular Drugs. 2009, Springer, New York.
97. [97] Zhao, Xd, Song, Lz, Zhang, Zh, et al. Adsorption investigation of Ma-Dtpa chelating resin for Ni(Ii) and Cu(II) using experimental and DFT methods. J. Mol. Struct. 986 (2011), 68–74.
98. [98] Sua, Fang-Yi, Linb, Kun-Ju, Sonajea, Kiran, et al. Protease inhibition and absorption enhancement by functional nanoparticles for effective oral insulin delivery. Biomaterials 33:9 (2012), 2801–2811.
99. [99] Ansari, M.J., Oral delivery of insulin for treatment of diabetes: classical challenges and current opportunities. J. Med. Sci. 15:5 (2015), 209–220.
100. [100] L. Hovgaard, H. Refsgaard, T.B. Kjeldsen, et al., Pharmaceutical Composition For Oral Insulin Administration Comprising A Tablet Core And An Anionic Copolymer Coating, Wo 2015010927 A1.2015.
101. [101] Aboofazeli, R., Peptide and protein delivery at a glance. Iran J. Pharm. Res., 2, 2003, 1.
102. [102] Smart, A.L., Gaisford, S., Basit, A.W., Oral peptide and protein delivery: intestinal obstacles and commercial prospects. Expert Opin. Drug Deliv. 11:8 (2014), 1323–1335.
103. [103] Kinesh, V.P., Neelam, D.P., Punit, B.P., et al. Novel approaches for oral delivery of insulin and current status of oral insulin products. Int. J. Pharm. Sci. Nanotechnol. 3:3 (2010), 1057–1064.
104. [104] Neha, P., Tanuj, J., A review on novel approaches for oral delivery of insulin. J. Drug Del. Ther. 5:4 (2015), 61–70.
105. [105] Cilek, A., Celebi, N., Tirnaksiz, F., et al. A lecithin-based microemulsion of rh-insulin with aprotinin for oral administration: Investigation of hypoglycemic effects in non-diabetic and STZ-induced diabetic rats. Int. J. Pharm. 298:1 (2005), 176–185.
106. [106] Ansari, M.J., Role of protease inhibitors in Insulin therapy of diabetes: are these beneficial?. Bull. Environ. Pharmacol. Life Sci. 4:11 (2015), 1–8.
107. [107] Milletti, F., Cell-penetrating peptides: classes, origin, and current landscape. Drug Discov. Today 17:15–16 (2012), 850–860.
108. [108] Ramsey, J.D., Flynn, N.H., Cell-penetrating peptides transport therapeutics into cells. Pharmacol. Therap. 154 (2015), 78–86.
109. [109] Zhang, D., Wang, J., Xu, D., Cell-penetrating peptides as noninvasive transmembrane vectors for the development of novel multifunctional drug-delivery systems. J. Control. Release 229 (2016), 130–139.
110. [110] Kristensen, M., Birch, D., Nielsen, H.M., Applications and challenges for use of cell-penetrating peptides as delivery vectors for peptide and protein cargos. Int. J. Mol. Sci. 17:2 (2016), 185–202.
111. [111] Kamei, N., Aoyama, Y., Khafagy, E., et al. Effect of different intestinal conditions on the intermolecular interaction between insulin and cell-penetrating peptide penetratin and on its contribution to stimulation of permeation through intestinal epithelium. Eur. J. Pharm. Biopharm. 94 (2015), 42–51.
112. [112] Araújo, F., Shrestha, N., Gomes, M.J., et al. In vivo dual-delivery of glucagon like peptide-1 (GLP-1) and dipeptidyl peptidase-4 (DPP4) inhibitor through composites prepared by microfluidics for diabetes therapy. Nanoscale 8:20 (2016), 10706–10713.
113. [113] Sheng, J., He, H., Han, L., et al. Enhancing insulin oral absorption by using mucoadhesive nanoparticles loaded with LMWP-linked insulin conjugates. J. Control. Release 233 (2016), 181–190.
114. [114] Khafagy, E.S., Morishita, M., Kamei, N., et al. Efficiency of cell-penetrating peptides on the nasal and intestinal absorption of therapeutic peptides and proteins. Int. J. Pharm. 381:1 (2009), 49–55.
115. [115] Shahid, K., Mayank, V., Geeta, A., et al. Mucoadhesive drug delivery systems, a review. World J. Pharm. Pharm. Sci. 5:5 (2016), 362–405.
116. [116] Varshney, H.M., Kumar, R., Mohan, S., Novel approaches for insulin delivery: current status. Int. J. Ther. App. 7 (2012), 25–31.
117. [117] Russo, E., Selmi, F., Baldassari, S., et al. A focus on mucoadhesive polymers and their application in buccal dosage forms. J. Drug Deliv. Sci. Technol. 32 (2016), 113–125.
118. [118] Andreani, T., de Souza, A.L.R., Kiill, C.P., et al. Preparation and characterization of PEG-coated silica nanoparticles for oral insulin delivery. Int. J. pharma. 473:1–2 (2014), 627–635.
119. [119] Shinde, P.V., Novel carrier systems for oral delivery of insulin. Asian J. Pharm. Tech. Inno. 1:2 (2013), 1–9.
120. [120] Mrsny, R.J., Daugherty, A., Proteins and Peptides: Pharmacokinetic, Pharmacodynamic, and Metabolic Outcomes. 2010, Taylor & Francis Group, Boca Raton.
121. [121] Li, X., Wang, C., Liang, R., et al. The glucose-lowering potential of exenatide delivered orally via goblet cell- targeting nanoparticles. Pharm. Res. 32:3 (2015), 1017–1027.
122. [122] Wang, J., Xu, M., Cheng, X., et al. Positive/negative surface charge of chitosan based nanogels and its potential influence on oral insulin delivery. Carbohyd. Polym. 136 (2016), 867–874.
123. [123] Shrestha, N., Araújo, F., Shahbazi, M.A., et al. Oral hypoglycaemic effect of GLP-1 and DPP4 inhibitor based nanocomposites in a diabetic animal model. J. Control. Release 232 (2016), 113–119.
124. [124] Gupta, V., Hwang, B., Doshi, N., et al. Delivery of exenatide and insulin using mucoadhesive intestinal devices. Ann. Biomed. Eng. 44:6 (2016), 1993–2007.
125. [125] Sakloetsakun, D., Bernkop-Schnürch, A., Thiolated chitosan. J. Drug Del. Sci. Tech. 20 (2010), 63–69.
126. [126] Hintzen, F., Perera, G., Hauptstein, S., et al. In vivo evaluation of an oral self-microemulsifying drug delivery system (SMEDDS) for leuprorelin. Int. J. Pharm. 472:1–2 (2014), 20–26.
127. [127] Sakloetsakun, D., Dünnhaupt, S., Barthelmes, J., et al. Combining two technologies: multifunctional polymers and self-nanoemulsifying drug delivery system (SNEDDS) for oral insulin administration. Int. J. Biol. Macromol. 61 (2013), 363–372.
128. [128] Straccia, M.C., D'Ayala, G.G., Romano, I., et al. Alginate hydrogels coated with chitosan for wound dressing. Mar. Drug. 13:5 (2015), 2890–2908.
129. [129] Omer, A.M., Tamer, T.M., Hassan, M.A., et al. Development of amphoteric alginate/aminated chitosan coated microbeads for oral protein delivery. Int. J. Biol. Macromol. 92 (2016), 362–370.
130. [130] Zhang, Y., Wei, W., Lv, P., et al. Preparation and evaluation of alginate-chitosan microspheres for oral delivery of insulin. Eur. J. Pharm. Biopharm. 77:1 (2011), 11–19.
131. [131] D'Souza, B., Bhowmik, T., Uddin, M.N., et al. Development of β-cyclodextrin-based sustained release microparticles for oral insulin delivery. Drug Dev. Ind. Pharm. 41:8 (2015), 1288–1293.
132. [132] Hasan, A.S., Sapin, A., Damge, C., et al. Reduction of the in vivo burst release of insulin-loaded microparticles. J. Drug Del. Sci. Technol. 30 (2015), 486–493.
133. [133] Zhang, B., He, D., Fan, Y., et al. Oral delivery of exenatide via microspheres prepared by cross-linking of alginate and hyaluronate. PLoS ONE, 9, 2014, e86064, 10.1371/journal.pone.0086064.
134. [134] Suri, S.S., Fenniri, H., Singh, B., Nanotechnology-based drug delivery systems. J. Occup. Med. Toxicol., 2, 2007, 16.
135. [135] Kumari, A., Yadav, S.K., Yadav, S.C., Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf. B 75:1 (2010), 1–18.
136. [136] Herrero, E.P., Alonso, M.J., Csaba, N., Polymer-based oral peptide nanomedicines. Ther. Deliv. 3:5 (2012), 657–668.
137. [137] Patel, A., Patel, M., Yang, X., et al. Recent advances in protein and peptide drug delivery: a special emphasis on polymeric nanoparticles. Protein Pept. Lett. 21:11 (2014), 1102–1120.
138. [138] Roger, E., Lagarce, F., Garcion, E., et al. Biopharmaceutical parameters to consider in order to alter the fate of nanocarriers after oral delivery. Nanomedicine (Lond.) 5:2 (2015), 287–306.
139. [139] Jung, T., Kamm, W., Breitenbach, A., et al. Biodegradable nanoparticles for oral delivery of peptides: is there a role for polymers to affect mucosal uptake?. Eur. J. Pharm. Biopharm. 50:1 (2000), 147–160.
140. [140] Galindo-Rodriguez, S.A., Allemann, E., Fessi, H., et al. Polymeric nanoparticles for oral delivery of drugs and vaccines: a critical evaluation of in vivo studies. Crit. Rev. Ther. Drug Carrier Syst. 22:5 (2005), 419–464.
141. [141] Damgé, C., Reis, C.P., Maincent, P., Strategies for the oral delivery of insulin. Expert Opin. Drug Deliv. 5:1 (2008), 45–68.
142. [142] Rick, S., Oral protein and peptide drug delivery. Binghe, W., Teruna, S., Richard, S., (eds.) Drug Delivery: Principles and Applications, 2005, Wiley Interscience, New Jersey.
143. [143] Bansal, T., Jaggi, M., Khar, R.K., Emerging significance of flavonoids as P-glycoprotein inhibitors in cancer chemotherapy. J. Pharm. Pharm. Sci. 12:1 (2009), 46–78.
144. [144] Xu, X., Li, R., Ma, M., et al. Multidrug resistance protein P-glycoprotein does not recognize nanoparticle C60: experiment and modeling. Soft Matter 8 (2012), 2915–2923.
145. [145] Van der Valle, C., Peptide and Protein Delivery. 1st ed., 2011, Elsevier Inc.
146. [146] Nguyen, H.N., Wey, S.P., Juang, J.H., et al. The glucose-lowering potential of exendin-4 orally delivered via a pH-sensitive nanoparticle vehicle and effects on subsequent insulin secretion in vivo. Biomaterials 32:10 (2011), 2673–2682.
147. [147] Salvionia, L., Fiandrab, L., Curtoc, M.D.D., et al. Oral delivery of insulin via polyethylene imine-based nanoparticles for colonic release allows glycemic control in diabetic rats. Pharmacol. Res. 110 (2016), 122–130.
148. [148] Li, L., Jiang, G., Yu, W., et al. A composite hydrogel system containing glucose-responsive nanocarriers for oral delivery of insulin. Mater. Sci. Eng., C 69 (2016), 37–45.
149. [149] Rawat, M., Singh, D., Saraf, S., et al. Nanocarriers: promising vehicle for bioactive drugs. Biol. Pharm. Bull. 29:9 (2006), 1790–1798.
150. [150] Souto, E.B., Müller, R.H., Lipid nanoparticles (SLN and NLC) for drug delivery. Domb, A.J., Tabata, Y., Kumar, M.N.V.R., et al. (eds.) Nanoparticles for Pharmaceutical Applications, 2007, American Scientific Publishers.
151. [151] Muller, R.H., Lippacher, A., Gohala, S., Solid lipid nanoparticles (SLN) as carrier system for the controlled release of drugs. Wise, D.L., (eds.) Handbook of Pharmaceutical Controlled Release Technology, 2000, Marcel Dekker.
152. [152] Moritz, M.G., Moritz, M., Solid lipid nanoparticles as attractive drug vehicles: composition, properties and therapeutic strategies. Mater. Sci. Eng. 68 (2016), 982–994.
153. [153] Fricker, G., Kromp, T., Wendel, A., Phospholipids and lipid-based formulations in oral drug delivery. Pharm. Res. 27:8 (2010), 1469–1486.
154. [154] Boushra, M., Tous, S., Fetih, G., et al. Development and evaluation of viscosity-enhanced nanocarrier (VEN) for oral insulin delivery. Int. J. Pharm. 511:11 (2016), 462–472.
155. [155] Boushra, M., Tous, S., Fetih, G., et al. Methocel-lipid hybrid nanocarrier for efficient oral insulin delivery. J. Pharm. Sci. 105:5 (2016), 1733–1740.
156. [156] Araújo, F., Shrestha, N., Shahbazi, M.A., et al. The impact of nanoparticles on the mucosal translocation and transport of GLP-1 across the intestinal epithelium. Biomaterials 35:33 (2014), 9199–9207.
157. [157] Shahbazi, M.A., Almeida, P.A., Mäkilä, E.M., et al. Augmented cellular trafficking and endosomal escape of porous silicon nanoparticles via zwitterionic bilayer polymer surface engineering. Biomaterials 35:26 (2014), 7488–7500.
158. [158] Alai, M.S., Lin, W.J., Pingale, S.S., Application of polymeric nanoparticles and micelles in insulin oral delivery. J. Food Drug Anal. 23:3 (2015), 351–358.
159. [159] Zhang, Z.H., Abbad, S., Pan, R.R., et al. N-octyl-N-Arginine chitosan micelles as an oral delivery system of insulin. J. Biomed. Nanotechnol. 9:4 (2013), 601–609.
160. [160] Allen, T.M., Cullis, P.R., Liposomal drug delivery systems: from concept to clinical applications. Adv. Drug Deliv. Rev. 65 (2013), 36–48.
161. [161] Thirawong, N., Thongborisute, J., Takeuchi, H., Sriamornsak, P., Improved intestinal absorption of calcitonin by mucoadhesive delivery of novel pectin-liposome nanocomplexes. J. Control. Release 125:3 (2008), 236–245.
162. [162] Degim, Z., Unal, N., Essiz, D., Abbasoglu, U., The effect of various liposome formulations on insulin penetration across Caco-2 cell monolayer. Life Sci. 75:23 (2004), 2819–2827.
163. [163] Niu, M., Lu, Y., Hovgaard, L., et al. Liposomes containing glycocholate as potential oral insulin delivery systems: preparation, in vitro characterization, and improved protection against enzymatic degradation. Int. J. Nanomed. 6 (2011), 1155–1166.
164. [164] M. Niu, Y. Lu, L. Hovgaard, et al. Hypoglycemic activity and oral bioavailability of insulin-loaded liposomes containing bile salts in rats: the effect of cholate type, particle size and administered dose 81(2) (2012) 265–272.
165. [165] Zhang, X., Qi, J., Lu, Y., et al. Biotinylated liposomes as potential carriers for the oral delivery of insulin. Nanomed. Nanotech. Biol. Med. 10:1 (2014), 167–176.
166. [166] Muzaffar, F., Singh, U.K., Chauhan, L., Review on microemulsion as futuristic drug delivery. Int. J. Pharm. Pharm. Sci. 5:3 (2013), 39–53.
167. [167] Talegaonkar, S., Azeem, A., Ahmad, F.J., et al. Microemulsions: a novel approach to enhanced drug delivery. Recent Pat. Drug Deliv. Formul. 2:3 (2008), 238–257.
168. [168] Sharma, G., Wilson, K., Van der Walle, C.F., Microemulsions for oral delivery of insulin: design, development and evaluation in streptozotocin induced diabetic rats. Eur. J. Pharm. Biopharm. 76:2 (2010), 159–169.
169. [169] R.S. Mody, A.K. Gupta, S. Paul, Microemulsion formulation for biologicals, WO 2011004395 A1.2011.
170. [170] Oral Pharmaceutical Formulation of BCS Class III Molecules, US 20150165032 A1.2015.
171. [171] Gupta, S., Chakraborty, Jain A., et al. Oral delivery of therapeutic proteins and peptides: a review on recent developments. Drug Del. 20:6 (2013), 237–246.
172. [172] Pridgen, E.M., Alexis, F., Farokhzad, O.C., Polymeric nanoparticle drug delivery technologies for oral delivery applications. Exp Opin. On Drug Del. 12:9 (2015), 1459–1473.
173. [173] Szymańska, E., Winnicka. stability of chitosan—a challenge for pharmaceutical and biomedical applications. Mar. Drugs 13:4 (2015), 1819–1846.
174. [174] Sharma, S., Parmar, A., Kori, S., et al. PLGA-based nanoparticles: a new paradigm in biomedical applications. TrAC, Trends Anal. Chem. 80 (2016), 30–40.
175. [175] Jayanth, P., Manisha, M.D., Sanjeeb, K.S., et al. Polymer degradation and in vitro release of a model protein from poly(D,L-lactide-co-glycolide) nano and microparticles. J. Control. Release 92 (2003), 173–187.
176. [176] Danhier, F., Ansorena, E., Silva, J.M., et al. PLGA-based nanoparticles: an overview of biomedical applications. J. Control. Release 161:2 (2012), 505–522.
177. [177] Jannin, V., Dellera, E., Chevrier, S., et al. In vitro lipolysis tests on lipid nanoparticles: comparison between lipase/co-lipase and pancreatic extract. Drug Dev. Ind. Pharm. 4:10 (2015), 1582–1588.
178. [178] Müller, R.H., Shegokar, R., Keck, C.M., 20 years of lipid nanoparticles (SLN & NLC): present state of development & industrial applications. Curr. Drug Discov. Technol. 8:3 (2011), 207–227.
179. [179] Ekambaram, P., Sathali, A., Priyanka, K., Solid lipid nanoparticles: a review. Sci. Rev. Chem. Commun. 2:1 (2012), 80–102.
180. [180] Latorre, A.C., Ravaghi, M., Manca, M.L., et al. Freeze-dried eudragit-hyaluronan multicompartment liposomes to improve the intestinal bioavailability of curcumin. Eur. J. Pharm. Biopharm. 107 (2016), 49–55.
181. [181] Gowthamarajan, K., Kulkarn, G.T., Oral insulin-fact or fiction? Possibilities of achieving oral delivery for insulin. Resonance 8:5 (2003), 38–46.
182. [182] Alai, M.S., Lin, W.J., Pingale, S.S., Application of polymeric nanoparticles and micelles in insulin oral delivery. J. Food Drug Anal. 23:3 (2015), 351–358.
183. [183] Yokoyama, M., Polymeric micelles as drug carriers: their lights and shadows. J. Drug Target. 22:7 (2014), 576–583.
184. [184] Marais, E., Hamman, J., Plessis, L.D., Lemmer, R., et al. Eudragit® L100/N-trimethylchitosan chloride microspheres for oral insulin delivery. Molecules 18:6 (2013), 6734–6747.
185. [185] Mitragotri, S., Burke, P.A., Langer, R., Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies. Nat. Rev. Drug Discov. 13:9 (2014), 655–672.
186. [186] Liu, D., Kobayashi, T., Russo, S., et al. In vitro and in vivo evaluation of a water-in-oil microemulsion system for enhanced peptide intestinal delivery. AAPS J. 15:1 (2014), 288–298.
187. [187] Cheng, M.B., Wang, J.C., Li, Y.H., et al. Characterization of water-in-oil microemulsion for oral delivery of earthworm fibrinolytic enzyme. J. Control. Release 129:1 (2008), 41–48.
188. [188] Madhav, S., Gupta, D., A review on microemulsion based system. IJPSR 2:8 (2011), 1888–1899.
189. [189] Senthil, K.K., Dhachinamoorthi, D., Saravanan, R., Microemulsions as carrier for novel drug delivery: a review. Int. J. Pharm. Sci. Rev. Res. 10:2 (2011), 37–45.
190. [190] Sruthi, S., Dhivya Priya, S., Hema, R., et al. Microemulsion – prophesy of drug delivery system. World J. Pharm. Sci. 3:10 (2014), 1800–1809.
191. [191] Andreania, T., Miziara, L., Lorenzón, E.N., et al. Effect of mucoadhesive polymers on the in vitro performance of insulin-loaded silica nanoparticles: Interactions with mucin and biomembrane models. Eur. J. Pharm. Biopharm. 93 (2015), 118–126.
192. [192] Morishita, M., Peppas, A.N., Is the oral route possible for peptide and protein drug delivery?. Drug Discov. Today 11:19–20 (2006), 905–910.
193. [193] Zhu, S., Chen, S., Gao, Y., et al. Enhanced oral bioavailability of insulin using PLGA nanoparticles co-modified with cell-penetrating peptides and Engrailed secretion peptide (Sec). Drug Deliv. 23:6 (2016), 1980–1991.
194. [194] Bashyal, S., Noh, G., Keum, T., et al. Cell penetrating peptides as an innovative approach for drug delivery; then, present and the future. J. Pharm. Invest. 46:3 (2016), 205–220.
195. [195] Dinca, A., Chien, W.M., Chin, M.T., Intracellular delivery of proteins with cell-penetrating peptides for therapeutic uses in human disease. Int. J. Mol. Sci. 17:2 (2016), 263–276.
196. [196] Williams, A.C., Barry, B.W., Penetration enhancers. Adv. Drug Deliv. Rev. 64 (2012), 128–137.
197. [197] Brayden, D.J., Mrsny, R.J., Oral peptide delivery prioritizing the leading technologies. Ther. Deliv. 2:12 (2011), 1567–1573.
198. [198] Krishnan, S.U., Sudhakar, Oral insulin – a challenging approach in insulin delivery. World. J. Pharm. Pharm. Sci. 4:10 (2015), 404–420.
199. [199] Mishra, M., Handbook of Encapsulation and Controlled Release. Polymeric Nano/Microparticles for Oral Delivery of Proteins and Peptides. 2016, Taylor & Francis Group, 1361.
200. [200] Schellekens, H., Hennink, W.E., Brinks, V., The immunogenicity of polyethylene glycol: facts and fiction. Pharm. Res. 30:7 (2013), 1729–1734.
201. [201] Li, Y., et al. Variant fatty acid-like molecules conjugation, novel approaches for extending the stability of therapeutic peptides. Sci. Rep., 5, 2015, 18039, 10.1038/srep18039.
202. [202] Zhang, F., Liu, M., Wan, H., Discussion about several potential drawbacks of pegylated therapeutic proteins. Biol. Pharm. Bull. 37:3 (2014), 335–339.
203. [203] Pallagi, E., Karimi, K., Ambrus, R., et al. New aspects of developing a dry powder inhalation formulation applying the quality-by-design approach. Int. J. Pharm. 511:1 (2016), 151–160.
204. [204] Pallagi, E., Ambrus, R., Szabo-Revesz, P., et al. Adaptation of the quality by design concept in early pharmaceutical development of an intranasal nanosized formulation. Int. J. Pharm. 491:1–2 (2015), 384–392.
205. [205] Kovacs, A., Erős, I., Csoka, I., Optimization and development of stable w/o/w cosmetic multiple emulsions by means of the quality by design approach. Int. J. Cosm. Sci. 38:2 (2016), 128–138.
206. [206] Kovács, A., Berkó, S.Z., Csányi, E., Development of nanostructured lipid carriers containing salicylic acid for dermal use based on the quality by design method. Eur. J. Pharm. Sci. 99 (2017), 246–257.
207. [207] Karimi, K., Pallagi, E., Szabó-Révész, P., Development of a microparticle-based DPI formulation of ciprofloxacin hydrochloride applying the QbD approach. Drug Des. Devel. Ther. 10 (2016), 3331–3343.
208. [208] Csoka, I., Pallagi, E., Kovacs, A., Regulatory science based drug formulation -model proposal for QBD in R&D phase. 11th Central European Symposium on Pharmaceutical Technology, Belgrad, Conference Abstract Book, 2016, 33.
209. [209] Quality by Design for Biotechnology Products—Part 1, A PhRMA Working Group's advice on applying QbD to biotech. BioPharm International, vol. 22, Issue 11, 2009.
210. [210] ICH guideline Q8 (R2) on pharmaceutical development, EMA, 2014, < http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002872.pdf>.
211. [211] ICH guideline Q9 on quality risk management, EMA, 2014, < http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002873.pdf>.
212. [212] ICH guideline Q10 on pharmaceutical quality system, EMA, 2014, < http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002871.pdf>.